31 / 43
Predictive Factors of long-term outcome with PRRT
Ezziddin S et al. J Nucl Med 2014
•
74 patients GEP-NET
•
177
Lu-octreotate (mean activity of 7.9 GBq per cycle x 4 cycles at standard intervals of 3 months
•
Response rate.- 36.5% partial response.
•
Median progression-free survival 26 months (95% confidence interval, 18.3–33.7)
•
Overall survival 55 months (95% confidence interval, 48.8–61.2).
Parameter
Overall Survival (p value)
Ki67 index
≤10% vs >10%
0.021
Performance status
>70% vs ≤70%
0.003
NSE Levels
<15 ng/ml vs ≥15 ng/ml
0.032
Hepatic tumor burden
<25% vs ≥25%
0.007